Iberdomide: cereblon E3 ligase modulator (CELMoD): treatment of systemic lupus erythematosus: treatment of multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F21%3A00013199" target="_blank" >RIV/00023736:_____/21:00013199 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1358/dof.2021.46.2.3223385" target="_blank" >https://doi.org/10.1358/dof.2021.46.2.3223385</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1358/dof.2021.46.2.3223385" target="_blank" >10.1358/dof.2021.46.2.3223385</a>
Alternative languages
Result language
angličtina
Original language name
Iberdomide: cereblon E3 ligase modulator (CELMoD): treatment of systemic lupus erythematosus: treatment of multiple myeloma
Original language description
Iberdomide (CC-220) is a cereblon (CRBN)-binding drug with antitumor and immunostimulatory activities.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Drugs of the future
ISSN
0377-8282
e-ISSN
—
Volume of the periodical
46
Issue of the periodical within the volume
2
Country of publishing house
ES - SPAIN
Number of pages
14
Pages from-to
115-127
UT code for WoS article
000620601800002
EID of the result in the Scopus database
2-s2.0-85114867919